ClinicalTrials.Veeva

Menu

Chinese Medicine in Treating Insomnia

The Chinese University of Hong Kong logo

The Chinese University of Hong Kong

Status and phase

Not yet enrolling
Phase 2

Conditions

Insomnia Chronic

Treatments

Drug: Modified Suan ZaoRen Tang-TianWang BuXin Dan
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT06511011
Insomnia study

Details and patient eligibility

About

This is a randomized, double-blinded, placebo-controlled clinical trial. Eligible participants will randomized into either treatment group (CM granules) or placebo group (placebo granules) for 6 weeks, followed by a post-treatment visit at week 9. The primary outcome is the change in Pittsburgh Sleep Quality Index (PSQI) at week 6.

Full description

Insomnia is one of the most general health concerns in the society. It is generally defined as a self-reported sleep disorder problem of the patient, characterized by difficulty in falling asleep, or difficulty maintaining sleep. According to American Insomnia Survey, 42.6% of the respondents reported of having at least one of the insomnia symptoms.

Chinese medicine can be an alternative to the treatment of insomnia. Suan Zao Ren Tang and Tian Wang Bu Xin Dan are two of the most common Chinese herbal formulae to treat insomnia, for which Suan Zao Ren Tang has the functions to nourish blood and calm the mind, clear heat and alleviate vexation, and Tian Wang Bu Xin Dan has the function to nourish the heart and calm the mind, and nourish Yin and clear heat. In this study, we will modify the formula of Suan ZaoRen Tang with TianWang BuXin Dan, and observe the effectiveness and safety of the study drug.

Enrollment

76 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age from 18 to 65 years;
  • Eligible for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, criteria for insomnia disorder. The criteria include having difficulties in falling asleep, difficulties in staying asleep, or early morning awakening with clinically significant consequences for daily life for at least 3 nights per week for at least 6 months;
  • Insomnia Severity Index (ISI) total score of at least 8 indicating insomnia at the clinical level;
  • Diagnosed to be Yin deficiency-induced internal heat pattern according to traditional Chinese Medicine (TCM) theory;
  • Able to complete questionnaires and take medications as scheduled; and
  • Voluntary written consent.

Exclusion criteria

  • Known nervous system disease (eg, stroke, Parkinson's Disease);
  • Known mental disorders (eg, depression or anxiety) or HADS score 11 or above in any either item;
  • Known sleeping related diseases (eg. sleep apnea, nocturnal myoclonus, restless legs, severe nocturnal enuresis or narcolepsy) that may affect the sleeping quality;
  • Known pharmacologically induced insomnia;
  • With symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturition, and cough;
  • Know treatment to comorbid sleep disorders, such as sleep apnea or narcolepsy;
  • Work on shift or on night shift;
  • Concomitant pharmacological treatment or herbal medicines for insomnia within the past month;
  • Known severe medical conditions, such as cardiovascular, liver, kidney or hematopoietic system disease, diabetes mellitus, cancers, cerebrovascular diseases;
  • Impaired hematological profile and liver / renal function exceeds the upper limit of the reference value by 2 times;
  • Known alcohol and / or drug abuse;
  • Known allergic history to any Chinese herbal medicines;
  • Diagnosed to be deficiency of spleen according to TCM theory;
  • Any contraindications for taking Chinese medicines in the opinion of the investigators;
  • Know pregnant or lactating; and
  • Involved in other interventional clinical studies at the same time.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

76 participants in 2 patient groups, including a placebo group

mSZT-TBD granules
Experimental group
Description:
Modified Suan ZaoRen Tang-TianWang BuXin Dan granules
Treatment:
Drug: Modified Suan ZaoRen Tang-TianWang BuXin Dan
Placebo granules
Placebo Comparator group
Description:
Placebo granules
Treatment:
Drug: Placebo

Trial contacts and locations

0

Loading...

Central trial contact

Cho Wing Lo; Zhixiu Lin

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems